NCT03662919

One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi or Imraldi: a French Cohort Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,274 (actual)
• Sponsor: Biogen · Industry
• Sex: All
• Age: 6 Years
• Healthy volunteers: Not accepted

Summary

A study to describe the one-year persistence in participants treated by Flixabi (infliximab) or Imraldi (Adalimumab) as prescribed by the physician for each of the 5 following indications: Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Crohn's Disease (CD) \[adults and children\] and Ulcerative Colitis (UC) \[adults for both treatments and children only for Flixabi\].

Conditions

• Arthritis, Rheumatoid
• Spondylitis, Ankylosing
• Arthritis, Psoriatic
• Crohn's Disease
• Colitis, Ulcerative

Interventions

Type	Name	Description
DRUG	Infliximab	Administered as specified in the treatment arm.
DRUG	Adalimumab	Administered as specified in the treatment arm.

Timeline

• Start date: 2018-07-02
• Primary completion: 2022-06-30
• Completion: 2022-06-30
• First posted: 2018-09-10
• Last updated: 2022-10-18

Locations

60 sites across 1 country: France

Regulatory

• FDA-regulated drug study